Abnormal hedgehog pathway in myelodysplastic syndrome and its impact on patients' outcome

sem informação10012e491e493CNPQ - CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICOFAPESP - FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULOsem informaçãosem informaçã

Imatinib restores vasp activity and its interaction with zyxin in bcr-abl leukemic cells

Vasodilator-stimulated phosphoprotein (VASP) and Zyxin are interacting proteins involved in cellular adhesion and motility. PKA phosphorylates VASP at serine 157, regulating VASP cellular functions. VASP interacts with ABL and is a substrate of the BCR-ABL oncoprotein. The presence of BCR-ABL protein drives oncogenesis in patients with chronic myeloid leukemia (CML) due to a constitutive activation of tyrosine kinase activity. However, the function of VASP and Zyxin in BCR-ABL pathway and the role of VASP in CML cells remain unknown. In vitro experiments using K562 cells showed the involvement of VASP in BCR-ABL signaling. VASP and Zyxin inhibition decreased the expression of anti-apoptotic proteins, BCL2 and BCL-XL. Imatinib induced an increase in phosphorylation at Ser157 of VASP and decreased VASP and BCR-ABL interaction. VASP did not interact with Zyxin in K562 cells; however, after Imatinib treatment, this interaction was restored. Corroborating our data, we demonstrated the absence of phosphorylation at Ser157 in VASP in the bone marrow of CML patients, in contrast to healthy donors. Phosphorylation of VASP on Ser157 was restored in Imatinib responsive patients though not in the resistant patients. Therefore, we herein identified a possible role of VASP in CML pathogenesis, through the regulation of BCR-ABL effector proteins or the absence of phosphorylation at Ser157 in VASP.Vasodilator-stimulated phosphoprotein (VASP) and Zyxin are interacting proteins involved in cellular adhesion and motility. PKA phosphorylates VASP at serine 157, regulating VASP cellular functions. VASP interacts with ABL and is a substrate of the BCR-AB18532388395CNPQ - CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICOFAPESP - FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULOsem informaçãosem informaçã

Imatinib Restores Vasp Activity And Its Interaction With Zyxin In Bcr-abl Leukemic Cells

Vasodilator-stimulated phosphoprotein (VASP) and Zyxin are interacting proteins involved in cellular adhesion and motility. PKA phosphorylates VASP at serine 157, regulating VASP cellular functions. VASP interacts with ABL and is a substrate of the BCR-ABL oncoprotein. The presence of BCR-ABL protein drives oncogenesis in patients with chronic myeloid leukemia (CML) due to a constitutive activation of tyrosine kinase activity. However, the function of VASP and Zyxin in BCR-ABL pathway and the role of VASP in CML cells remain unknown. In vitro experiments using K562 cells showed the involvement of VASP in BCR-ABL signaling. VASP and Zyxin inhibition decreased the expression of anti-apoptotic proteins, BCL2 and BCL-XL. Imatinib induced an increase in phosphorylation at Ser157 of VASP and decreased VASP and BCR-ABL interaction. VASP did not interact with Zyxin in K562 cells; however, after Imatinib treatment, this interaction was restored. Corroborating our data, we demonstrated the absence of phosphorylation at Ser157 in VASP in the bone marrow of CML patients, in contrast to healthy donors. Phosphorylation of VASP on Ser157 was restored in Imatinib responsive patients though not in the resistant patients. Therefore, we herein identified a possible role of VASP in CML pathogenesis, through the regulation of BCR-ABL effector proteins or the absence of phosphorylation at Ser157 in VASP.18532388395Goss, V.L., Lee, K.A., Moritz, A., Nardone, J., Spek, E.J., MacNeill, J., Rush, J., Polakiewicz, R.D., A common phosphotyrosine signature for the Bcr-Abl kinase (2006) Blood, 107, pp. 4888-4897Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., Lydon, N.B., Sawyers, C.L., Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia (2001) N. Engl. J. Med., 344, pp. 1031-1037Kuroda, J., Puthalakath, H., Cragg, M.S., Kelly, P.N., Bouillet, P., Huang, D.C., Kimura, S., Strasser, A., Bim and Bad mediate imatinib-induced killing of Bcr/Abl+leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic (2006) Proc. Natl. Acad. Sci. U. S. A., 103, pp. 14907-14912Kuroda, J., Kimura, S., Strasser, A., Andreeff, M., O'Reilly, L.A., Ashihara, E., Kamitsuji, Y., Maekawa, T., Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia (2007) Cell Death Differ., 14, pp. 1667-1677Kuroda, J., Kimura, S., Andreeff, M., Ashihara, E., Kamitsuji, Y., Yokota, A., Kawata, E., Maekawa, T., ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms (2008) Br. J. Haematol., 140, pp. 181-190Ko, T.K., Chuah, C.T., Huang, J.W., Ng, K.P., Ong, S.T., The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors (2014) Oncotarget, 5, pp. 9033-9038Kuroda, J., Shimura, Y., Yamamoto-Sugitani, M., Sasaki, N., Taniwaki, M., Multifaceted mechanisms for cell survival and drug targeting in chronic myelogenous leukemia (2013) Curr. Cancer Drug Targets, 13, pp. 69-79Nadav, L., Katz, B.Z., The molecular effects of oncogenesis on cell-extracellular matrix adhesion (2001) Int. J. Oncol., 19, pp. 237-246Fogerty, F.J., Juang, J.L., Petersen, J., Clark, M.J., Hoffmann, F.M., Mosher, D.F., Dominant effects of the bcr-abl oncogene on Drosophila morphogenesis (1999) Oncogene, 18, pp. 219-232Salgia, R., Li, J.L., Ewaniuk, D.S., Pear, W., Pisick, E., Burky, S.A., Ernst, T., Griffin, J.D., BCR/ABL induces multiple abnormalities of cytoskeletal function (1997) J. Clin. Invest., 100, pp. 46-57Wertheim, J.A., Perera, S.A., Hammer, D.A., Ren, R., Boettiger, D., Pear, W.S., Localization of BCR-ABL to F-actin regulates cell adhesion but does not attenuate CML development (2003) Blood, 102, pp. 2220-2228Li, Y., Clough, N., Sun, X., Yu, W., Abbott, B.L., Hogan, C.J., Dai, Z., Bcr-Abl induces abnormal cytoskeleton remodeling, beta1 integrin clustering and increased cell adhesion to fibronectin through the Abl interactor 1 pathway (2007) J. Cell Sci., 120, pp. 1436-1446Ridley, A.J., Schwartz, M.A., Burridge, K., Firtel, R.A., Ginsberg, M.H., Borisy, G., Parsons, J.T., Horwitz, A.R., Cell migration: integrating signals from front to back (2003) Science, 302, pp. 1704-1709Whalen, A.M., Galasinski, S.C., Shapiro, P.S., Nahreini, T.S., Ahn, N.G., Megakaryocytic differentiation induced by constitutive activation of mitogen-activated protein kinase kinase (1997) Mol. Cell. Biol., 17, pp. 1947-1958Sperry, R.B., Bishop, N.H., Bramwell, J.J., Brodeur, M.N., Carter, M.J., Fowler, B.T., Lewis, Z.B., Hansen, M.D., Zyxin controls migration in epithelial-mesenchymal transition by mediating actin-membrane linkages at cell-cell junctions (2010) J. Cell. Physiol., 222, pp. 612-624Grange, J., Moody, J.D., Ascione, M.P., Hansen, M.D., Zyxin-VASP interactions alter actin regulatory activity in zyxin-VASP complexes (2013) Cell. Mol. Biol. Lett., 18, pp. 1-10Drees, B., Friederich, E., Fradelizi, J., Louvard, D., Beckerle, M.C., Golsteyn, R.M., Characterization of the interaction between zyxin and members of the Ena/vasodilator-stimulated phosphoprotein family of proteins (2000) J. Biol. Chem., 275, pp. 22503-22511Hansen, M.D., Beckerle, M.C., Opposing roles of zyxin/LPP ACTA repeats and the LIM domain region in cell-cell adhesion (2006) J. Biol. Chem., 281, pp. 16178-16188Benz, P.M., Blume, C., Seifert, S., Wilhelm, S., Waschke, J., Schuh, K., Gertler, F., Renne, T., Differential VASP phosphorylation controls remodeling of the actin cytoskeleton (2009) J. Cell Sci., 122, pp. 3954-3965Moody, J.D., Grange, J., Ascione, M.P., Boothe, D., Bushnell, E., Hansen, M.D., A zyxin head-tail interaction regulates zyxin-VASP complex formation (2009) Biochem. Biophys. Res. Commun., 378, pp. 625-628Harbeck, B., Huttelmaier, S., Schluter, K., Jockusch, B.M., Illenberger, S., Phosphorylation of the vasodilator-stimulated phosphoprotein regulates its interaction with actin (2000) J. Biol. Chem., 275, pp. 30817-30825Call, G.S., Chung, J.Y., Davis, J.A., Price, B.D., Primavera, T.S., Thomson, N.C., Wagner, M.V., Hansen, M.D., Zyxin phosphorylation at serine 142 modulates the zyxin head-tail interaction to alter cell-cell adhesion (2011) Biochem. Biophys. Res. Commun., 404, pp. 780-784Han, G., Fan, B., Zhang, Y., Zhou, X., Wang, Y., Dong, H., Wei, Y., Wei, L., Positive regulation of migration and invasion by vasodilator-stimulated phosphoprotein via Rac1 pathway in human breast cancer cells (2008) Oncol. Rep., 20, pp. 929-939Tao, Y., Chen, Y.C., Wang, Y., Zhang, Z.J., Xu, W.R., Phosphorylated vasodilator-stimulated phosphoprotein is localized on mitotic spindles of the gastric cancer cell line SGC-7901 (2006) World J. Gastroenterol., 12, pp. 7478-7481Sy, S.M., Lai, P.B., Pang, E., Wong, N.L., To, K.F., Johnson, P.J., Wong, N., Novel identification of zyxin upregulations in the motile phenotype of hepatocellular carcinoma (2006) Mod. Pathol., 19, pp. 1108-1116van der Gaag, E.J., Leccia, M.T., Dekker, S.K., Jalbert, N.L., Amodeo, D.M., Byers, H.R., Role of zyxin in differential cell spreading and proliferation of melanoma cells and melanocytes (2002) J. Investig. Dermatol., 118, pp. 246-254Stevens, T.L., Rogers, E.M., Koontz, L.M., Fox, D.T., Homem, C.C., Nowotarski, S.H., Artabazon, N.B., Peifer, M., Using Bcr-Abl to examine mechanisms by which abl kinase regulates morphogenesis in Drosophila (2008) Mol. Biol. Cell, 19, pp. 378-393Maruoka, M., Sato, M., Yuan, Y., Ichiba, M., Fujii, R., Ogawa, T., Ishida-Kitagawa, N., Watanabe, N., Abl-1-bridged tyrosine phosphorylation of VASP by Abelson kinase impairs association of VASP to focal adhesions and regulates leukaemic cell adhesion (2012) Biochem. J., 441, pp. 889-899Livak, K.J., Schmittgen, T.D., Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method (2001) Methods, 25, pp. 402-408Ren, X.D., Kiosses, W.B., Schwartz, M.A., Regulation of the small GTP-binding protein Rho by cell adhesion and the cytoskeleton (1999) EMBO J., 18, pp. 578-585Machado-Neto, J.A., Lazarini, M., Favaro, P., Franchi, G.C., Nowill, A.E., Saad, S.T., Traina, F., ANKHD1, a novel component of the Hippo signaling pathway, promotes YAP1 activation and cell cycle progression in prostate cancer cells (2014) Exp. Cell Res., 324, pp. 137-145Machado-Neto, J.A., Favaro, P., Lazarini, M., Costa, F.F., Olalla Saad, S.T., Traina, F., Knockdown of insulin receptor substrate 1 reduces proliferation and downregulates Akt/mTOR and MAPK pathways in K562 cells (2011) Biochim. Biophys. Acta, 1813, pp. 1404-1411Traina, F., Carvalheira, J.B., Saad, M.J., Costa, F.F., Saad, S.T., BCR-ABL binds to IRS-1 and IRS-1 phosphorylation is inhibited by imatinib in K562 cells (2003) FEBS Lett., 535, pp. 17-22Hernandez, S.E., Krishnaswami, M., Miller, A.L., Koleske, A.J., How do Abl family kinases regulate cell shape and movement? (2004) Trends Cell Biol., 14, pp. 36-44Fierro, F.A., Taubenberger, A., Puech, P.H., Ehninger, G., Bornhauser, M., Muller, D.J., Illmer, T., BCR/ABL expression of myeloid progenitors increases beta1-integrin mediated adhesion to stromal cells (2008) J. Mol. Biol., 377, pp. 1082-1093Pluk, H., Dorey, K., Superti-Furga, G., Autoinhibition of c-Abl (2002) Cell, 108, pp. 247-259Howe, A.K., Hogan, B.P., Juliano, R.L., Regulation of vasodilator-stimulated phosphoprotein phosphorylation and interaction with Abl by protein kinase A and cell adhesion (2002) J. Biol. Chem., 277, pp. 38121-38126Grevengoed, E.E., Fox, D.T., Gates, J., Peifer, M., Balancing different types of actin polymerization at distinct sites: roles for Abelson kinase and Enabled (2003) J. Cell Biol., 163, pp. 1267-1279Howe, A.K., Regulation of actin-based cell migration by cAMP/PKA (2004) Biochim. Biophys. Acta, 1692, pp. 159-174Weissinger, E.M., Oettrich, K., Evans, C., Genieser, H.G., Schwede, F., Dangers, M., Dammann, E., Kolch, W., Activation of protein kinase A (PKA) by 8-Cl-cAMP as a novel approach for antileukaemic therapy (2004) Br. J. Cancer, 91, pp. 186-192Sonoda, Y., Matsumoto, Y., Funakoshi, M., Yamamoto, D., Hanks, S.K., Kasahara, T., Anti-apoptotic role of focal adhesion kinase (FAK). Induction of inhibitor-of-apoptosis proteins and apoptosis suppression by the overexpression of FAK in a human leukemic cell line, HL-60 (2000) J. Biol. Chem., 275, pp. 16309-16315Ferrao, P.T., Frost, M.J., Siah, S.P., Ashman, L.K., Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro (2003) Blood, 102, pp. 4499-4503Dai, Y., Rahmani, M., Corey, S.J., Dent, P., Grant, S., A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2 (2004) J. Biol. Chem., 279, pp. 34227-3423

Computed tomography-based skeletal segmentation for quantitative PET metrics of bone involvement in multiple myeloma

FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESPPurpose: Quantifications in nuclear medicine are occasionally limited by the lack of standardization for defining volumes of interest (VOIs) on functional images. In the present article, we propose the use of computed tomography (CT)-based skeletal segmen414377382FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESPFUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESP2009/54065-02018/00654-4The authors would like to thank the Nuclear and Energy Research Institute (IPEN-CNEN), São Paulo, Brazil, for supplying the radiopharmaceuticals used in the present project (IPEN/UNICAMP agreement No. 01342000458/2017-15). The authors are grateful for th

Seasonal and spatial patterns in cellular energy allocation in the estuarine mysid Neomysis integer (Crustacea: Mysidacea) of the Scheldt estuary (The Netherlands)

Myelodysplastic syndromes (MDS) are clonal disorders involving hematopoietic stem cells (HSC) characterized by ineffective hematopoiesis. In addition to HSC defects, a defective hematopoiesis supporting capacity of mesenchymal stromal cells (MSCs) in the microenvironment niche has been implicated in MDS pathophysiology. The interaction between the dysfunctional MSCs MDS and HSC regulates diverse adhesion-related processes, such as progenitor cell survival, proliferation, differentiation, and self-renewal. As previously reported, a microarray analysis identified serine protease inhibitor kunitz-type 2 (SPINT2), an inhibitor of hepatocyte growth factor (HGF) activation, to be downregulated in MSCs from MDS patients. To define the role of SPINT2 in MDS hematopoietic microenvironment, an analysis of the effect of SPINT2 silencing in MSCs was carried out. We herein reported significantly lower levels of SPINT2 whereas HGF was expressed at higher levels in MSCs from MDS patients compared with healthy controls. SPINT2 underexpression results in an increased expression, production, and secretion of HGF and stromal cell-derived factor 1 (SDF-1) by MSCs. An increased adhesion of normal HSC or malignant cells onto MSCs silenced for SPINT2 was also observed. The altered MSCs adhesion in SPINT2-knockdown cells was correlated with increased CD49b and CD49d expression and with a decrease in CD49e expression. Our results suggest that the SPINT2 underexpression in the MSC from MDS patients is probably involved in the adhesion of progenitors to the bone marrow niche, through an increased HGF and SDF-1 signaling pathway.231109-2